Cohance Lifesciences (BOM:543064) Interest Expense: ₹-338 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543064 Cohance Lifesciences Ltd BOM:543064
88 GF Score
Price ₹462.60
GF Value ₹644.12
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Cohance Lifesciences Interest Expense?

Cohance Lifesciences BOM:543064 -2.72% 88 Interest Expense is ₹-338 Mil as of Jun. 2026. GuruFocus rates BOM:543064 with a GF Score™ of 88/100 and a GF Value™ of ₹644.12 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cohance Lifesciences's interest expense for the three months ended in Jun. 2026 was ₹ -67 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was ₹-338 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cohance Lifesciences's Operating Income for the three months ended in Jun. 2026 was ₹ -484 Mil. Cohance Lifesciences's Interest Expense for the three months ended in Jun. 2026 was ₹ -67 Mil. Cohance Lifesciences did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cohance Lifesciences  (BOM:543064) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cohance Lifesciences's Interest Expense for the three months ended in Jun. 2026 was ₹-67 Mil. Its Operating Income for the three months ended in Jun. 2026 was ₹-484 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2026 was ₹0 Mil.

Cohance Lifesciences's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

Cohance Lifesciences did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Cohance Lifesciences Interest Expense Historical Data

* Premium members only.

The historical data trend for Cohance Lifesciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cohance Lifesciences Interest Expense Chart

Cohance Lifesciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Interest Expense
Get a 7-Day Free Trial -62.31 -128.11 -69.50 -410.60 -372.40

Cohance Lifesciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -101.80 -87.60 -91.10 -91.90 -67.40
BOM:543064
88GF Score
Cohance Lifesciences Ltd BOM:543064
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cohance Lifesciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-338 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of ₹-338 Mil mean?
Cohance Lifesciences (BOM:543064) has a Interest Expense of ₹-338 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Cohance Lifesciences and its competitors.
Is Cohance Lifesciences' Interest Expense too high?
Cohance Lifesciences' current Interest Expense is ₹-338 Mil. Overall, Cohance Lifesciences has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cohance Lifesciences' Interest Expense compare to ZTS?
Cohance Lifesciences' Interest Expense of ₹-338 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Cohance Lifesciences and its competitors. Cohance Lifesciences's current Interest Expense is ₹-338 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cohance Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Cohance Lifesciences (BOM:543064) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹644.12, compared to a current price of ₹462.60 — trading 28.2% below its estimated fair value. The current Interest Expense is ₹-338 Mil. Cohance Lifesciences' overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Cohance Lifesciences (BOM:543064), the current Interest Expense is ₹-338 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cohance Lifesciences (BOM:543064) Overvalued in 2026?

Based on GuruFocus' analysis, Cohance Lifesciences stock appears to be undervalued. The current stock price of ₹462.60 is trading 28.2% below its estimated GF Value™ of ₹644.12. GuruFocus considers Cohance Lifesciences to be Modestly Undervalued.

Key valuation signals for BOM:543064:

  • Interest Expense: ₹-338 Mil
  • GF Value™: ₹644.12 vs. price of ₹462.60 (28.2% below fair value)
  • GF Score™: 88/100 with 8 warning signs

No single metric tells the full story. See the BOM:543064 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cohance Lifesciences Business Description

Other Exchanges COHANCE:India
Address Hitech City Road, Panmaktha Plot, 1, 202, 2nd Floor, B-Wing, Galaxy by Aurobindo Realty, Sy No 83/1, Hyderabad Knowledge City TSIIC Raidurg, Opposite IKEA, Hyderabad, TG, IND, 500081
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule's lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
88GF Score

Get the complete analysis for BOM:543064

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹462.60
Price
₹644.12
GF Value